Helius Medical Technologies (NASDAQ: HSDT), a neurotech company focused on neurological wellness, announced the pricing of a public offering of 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 36,000,000 shares of its Class A common stock (“public warrants”) at a purchase price of $0.75 per share and associated public warrant. According to the update, the public warrants will have an exercise price of $0.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. Roth Capital Partners acted as lead placement agent for the offering, which closed on Aug. 9, 2022.

To view the full press release, visit https://ibn.fm/LFsKI

About Helius Medical Technologies Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The company’s commercial product is the Portable Neuromodulation Stimulator (PoNS(TM)). For further information about the company, please visit www.HeliusMedical.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.